Analyst Price Target is $84.29
▲ +83.95% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for MoonLake Immunotherapeutics in the last 3 months. The average price target is $84.29, with a high forecast of $104.00 and a low forecast of $62.00. The average price target represents a 83.95% upside from the last price of $45.82.
Current Consensus is
Buy
The current consensus among 8 investment analysts is to buy stock in MoonLake Immunotherapeutics. This rating changed within the last month from a Moderate Buy consensus rating.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Read More